Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT) in patients with persistent hypercapnia following an acute exacerbation of chronic obstructive pulmonary disease delays hospital readmission. The economic impact of this treatment is unknown. We evaluated the cost-effectiveness of HMV in the UK healthcare system using data from a previously published efficacy trial. Quality-adjusted life-years (QALYs) were computed from EQ-5D-5L. Accounting for all direct patient costs HOT-HMV was £512 (95%CI £36 to £990) more expensive per patient per year than HOT-alone. This small increase in cost was accompanied by increased quality of life leading to an incremental cost-effectiveness ratio of £10 259 per QALY. HOT-HMV was cost-effective in this clinical population. Trial registration number: [NCT00990132][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00990132&atom=%2Fthoraxjnl%2F78%2F5%2F523.atom

中文翻译：

---

英国慢性阻塞性肺病急性加重后持续高碳酸血症患者家庭无创通气的成本效益

慢性阻塞性肺疾病急性加重后持续性高碳酸血症患者的家庭无创机械通气 (HMV) 和家庭氧疗 (HOT) 延迟了再入院时间。这种治疗的经济影响是未知的。我们使用先前发布的功效试验的数据评估了 HMV 在英国医疗保健系统中的成本效益。根据 EQ-5D-5L 计算质量调整生命年 (QALY)。考虑到所有直接的患者成本，HOT-HMV 比单独使用 HOT 的每位患者每年要贵 512 英镑（95%CI 36 至 990 英镑）。这种成本的小幅增加伴随着生活质量的提高，导致每个 QALY 的成本效益比增加 10,259 英镑。HOT-HMV 在该临床人群中具有成本效益。试用注册号：[NCT00990132][1]。[1]: